Kynamro was similar to Exondy’s in that both were knocked back by the review board and then approved by the FDA with conditions attached.
The fact Sarepta is still lagging years in delivering the further results maybe hurt the chances of their latest application ?
- Forums
- ASX - By Stock
- Sarepta's FDA rejection
PYC
pyc therapeutics limited
Add to My Watchlist
4.35%
!
$1.20

Kynamro was similar to Exondy’s in that both were knocked back...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.20 |
Change
0.050(4.35%) |
Mkt cap ! $699.9M |
Open | High | Low | Value | Volume |
$1.16 | $1.21 | $1.13 | $387.7K | 327.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2000 | $1.12 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.20 | 25000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2000 | 1.120 |
1 | 8968 | 1.115 |
3 | 9261 | 1.100 |
1 | 2000 | 1.050 |
2 | 33803 | 1.000 |
Price($) | Vol. | No. |
---|---|---|
1.200 | 25000 | 1 |
1.210 | 2832 | 1 |
1.220 | 2000 | 1 |
1.225 | 500 | 1 |
1.230 | 15000 | 1 |
Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |